Leuven, BELGIUM – July 10, 2025 at 5:45 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the fulfilment of the second condition precedent in the acquisition of 72% of the share capital of Axiodis CRO by its French subsidiary.
The French Ministry for the Economy, Finance and Industrial and Digital Sovereignty has confirmed that the planned transaction does not fall within the scope of foreign investment control in France, as set out in Article L.151-3 of the Monetary and Financial Code.
This decision clears the regulatory condition precedent related to the Foreign Direct Investment (FDI) procedure.
Oxurion is now finalizing the financing of the transaction with a view to closing within the next 30 days.
About Oxurion
Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments.
The Group's headquarters are located in Leuven, Belgium. More information: www.oxurion.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.
No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: mGdvlMablJqVnJ9qZ8lnbWRnZm6Uk2ebbWmWxGJolseVaGqWx2xqZ5zJZnJjnmxp
- Check this key: https://www.security-master-key.com.
Regulated information:
Inside Information:
- Operations of the issuer (acquisitions, salesâ¦)
Full and original press release in PDF: https://www.actusnews.com/news/92973-oxurion_pr_axiodi_condition-suspensive-fdi_en.pdf
Leuven, BELGIUM – July 10, 2025 at 5:45 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the fulfilment of the second condition precedent in the acquisition of 72% of the share capital of Axiodis CRO by its French subsidiary.
The French Ministry for the Economy, Finance and Industrial and Digital Sovereignty has confirmed that the planned transaction does not fall within the scope of foreign investment control in France, as set out in Article L.151-3 of the Monetary and Financial Code.
This decision clears the regulatory condition precedent related to the Foreign Direct Investment (FDI) procedure.
Oxurion is now finalizing the financing of the transaction with a view to closing within the next 30 days.
About Oxurion
Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments.
The Group's headquarters are located in Leuven, Belgium. More information: www.oxurion.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.
No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: mGdvlMablJqVnJ9qZ8lnbWRnZm6Uk2ebbWmWxGJolseVaGqWx2xqZ5zJZnJjnmxp
- Check this key: https://www.security-master-key.com.
Regulated information:
Inside Information:
- Operations of the issuer (acquisitions, salesâ¦)
Full and original press release in PDF: https://www.actusnews.com/news/92973-oxurion_pr_axiodi_condition-suspensive-fdi_en.pdf
www.actusnews.com, it's free